ArchiMed takes biopharma firm Esperion Therapeutics private for $1.1bn
Esperion focuses on bringing cardiometabolic and rare/orphan disease therapies to market. The post ArchiMed takes biopharma firm Esperion Therapeutics private for $1.1bn appeared first on PE Hub .
Read the full story at PE Hub →